Latest News and Press Releases
Want to stay updated on the latest news?
-
MONTREAL, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...
-
Theratechnologies développera la tésamoréline pour le traitement du NASH chez la population générale
Dépôt du protocole de phase 3 au 4ème trimestre 2020; Début de l’essai prévu tôt en 2021 L’étude clinique inclura une cohorte VIH MONTRÉAL, 10 sept. 2020 (GLOBE NEWSWIRE) -- Theratechnologies...
-
Phase 3 protocol to be filed in Q4 2020; trial expected to begin early 2021 Clinical study to include HIV cohort MONTREAL, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc....
-
Premier lancement commercial en Europe MONTRÉAL, 10 sept. 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), une société biopharmaceutique...
-
First commercial launch in Europe MONTREAL, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the...
-
MONTRÉAL, 30 juill. 2020 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies ») (TSX: TH) (NASDAQ: THTX), société biopharmaceutique au stade de l’exploitation commerciale, a annoncé...
-
MONTREAL, July 30, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that Philippe Dubuc,...
-
Sous-analyse de l’étude menée par le MGH aide à mieux démontrer comment la tésamoréline réduit le gras hépatique Impact positif de la tésamoréline sur la phosphorylation oxidative, l’inflammation,...
-
Sub-analysis of MGH study helps better demonstrate how tesamorelin reduces liver fat Positive impact of tesamorelin on oxidative phosphorylation, inflammation, tissue repair and cell division ...
-
MONTREAL, July 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of...